NICE recommends Lixiana (edoxaban) for prevention of recurrent deep vein thrombosis and pulmonary embolism- Daiichi Sankyo
The National Institute for Health and Care Excellence (NICE), the medicines cost-effectiveness body for England and Wales, has recommended a new treatment to help patients suffering from blood clots in the legs and lungs. Daiichi Sankyo announced that NICE has issued its final recommendation for Lixiana (edoxaban) for the treatment and prevention of recurrent deep vein thrombosis (DVT) and pulmonary embolism (PE) in adults.
The NICE recommendation comes shortly after edoxaban received European marketing authorisation in June 2015 for two indications:
- Treatment of DVT and PE, and prevention of recurrent DVT and PE in adults
- Prevention of stroke and systemic embolism (SE) in adult patients with nonvalvular atrial fibrillation (NVAF) with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack (TIA)
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.